Phyllanthus emblica and hovenia dulcis thunb tablet candy capable of protecting liver and resisting uric acid

Abstract

The invention belongs to the technical field of functional food, and relates to a liver-protecting and uric acid-resisting emblic leafflower fruit and hovenia dulcis thunb tablet candy, which comprises an emblic leafflower fruit extract, a hovenia dulcis thunb extract, prebiotics, a disintegrating agent, a flavoring agent and a lubricant, and the weight ratio of the emblic leafflower fruit extract to the hovenia dulcis thunb extract is (1.2-1.8): 1. The phyllanthus emblica and the hovenia dulcis thunb are compounded according to a specific ratio, so that the synergistic interaction of liver protection and uric acid reduction is realized in the tableted candy for the first time, and the xanthine oxidase inhibition rate is obviously higher than that of a single formula and a theoretical superposition value. A co-spray drying process is combined with fructo-oligosaccharide auxiliary materials, so that the stability of active ingredients is reserved, and the bitter taste of traditional Chinese medicines is improved.

Description

Technical Field

[0001] The invention belongs to the technical field of functional foods and relates to a liver-protecting and anti-uric acid candy containing emblica emblica and hovenia dulcis fruit tablets. Background Art

[0002] Uric acid and liver damage are becoming increasingly common, and modern people are increasingly prioritizing health preservation. To address these issues, people have gradually developed a habit of using both medicinal and edible ingredients in their daily lives. For liver damage, emblica fructus is widely used due to its rich content of ellagic acid and vitamin C, which have antioxidant and liver-protecting properties. Hovenia dulcis (Hovenia spinulosa) contains dihydromyricetin, which has a significant uric acid-lowering effect. However, no research has yet explored the rational combination of these two ingredients to achieve a synergistic effect in liver protection and uric acid reduction. Summary of the Invention

[0003] The purpose of the present invention is to solve the above problems and provide a liver-protecting and anti-uric acid candy made of emblica emblica and hovenia dulcis.

[0004] To achieve the above objectives, the present invention provides a liver-protecting and anti-uric acid-resistant emblica and Hovenia dulcis tablet candy, comprising emblica extract, Hovenia dulcis extract, a prebiotic, a disintegrant, a flavoring agent and a lubricant, wherein the weight ratio of the emblica extract to the Hovenia dulcis extract is (1.2-1.8):1.

[0005] Furthermore, by weight, the emblica fruit extract is 20%-40%, the Hovenia dulcis fruit extract is 15%-35%, the prebiotic is 10%-25%, the disintegrant is 5%-15%, the flavoring agent is 8%-20%, and the lubricant is 0.5%-2%.

[0006] Furthermore, the prebiotic is oligofructose, the disintegrant is microcrystalline cellulose, the flavoring agent is xylitol, and the lubricant is magnesium stearate.

[0007] The present invention also provides a method for preparing the above-mentioned liver-protecting and anti-uric acid-resistant emblica and hovenia dulcis tablet candy, comprising: S1. Grind the emblica fruit through a 60-mesh sieve and extract twice with ultrasonic wave at 60°C for 30 min each time using ethanol:water = 1:3 as solvent and solid-liquid ratio of 1:15 (g / mL). The combined extracts were concentrated to a solid content of 25%. S2. Grind the seeds of Hovenia dulcis and pass them through an 80-mesh sieve. Use pure water as the solvent at a solid-liquid ratio of 1:12 (g / mL). Perform heat extraction at 70°C twice, each time for 1.5 hours. Concentrate the combined extracts to a solid content of 25%. S3, mixing the concentrated solution obtained in S1 and the concentrated solution obtained in S2 in a volume ratio of 3:2, adding 20% ​​maltodextrin by weight of the mixed solution, and centrifugally spray drying to obtain a composite powder; S4, three-dimensionally mixing the composite powder with oligofructose and microcrystalline cellulose for 30 minutes, adding xylitol and mixing for 15 minutes, and finally adding magnesium stearate and mixing for 5 minutes; S5. Press into tablets under a pressure of 18±2KN.

[0008] The beneficial effects of the present invention are as follows: This invention, by combining Phyllanthus emblica and Hovenia dulcis in a specific ratio, achieves synergistic liver-protecting and uric acid-lowering effects in a compressed candy for the first time. Its xanthine oxidase inhibition rate significantly exceeds both the single formula and the theoretical combined value. The co-spray drying process combined with oligofructose excipients preserves the stability of the active ingredients while improving the bitter taste of traditional Chinese medicine. BRIEF DESCRIPTION OF THE DRAWINGS

[0009] Figure 1 The present invention schematically shows a preparation flow chart of the liver-protecting and anti-uric acid-resistant Emblic and Hovenia dulcis fruit tablet candy according to one embodiment of the present invention. DETAILED DESCRIPTION

[0010] To more clearly illustrate the embodiments of the present invention or the technical solutions in the prior art, the following briefly introduces the drawings required for the embodiments. Obviously, the drawings described below are only some embodiments of the present invention. For those skilled in the art, other drawings can be derived from these drawings without inventive effort.

[0011] The present invention will be described in detail below with reference to the accompanying drawings and specific embodiments. The embodiments cannot be described one by one here, but the embodiments of the present invention are not limited to the following embodiments.

[0012] The invention provides a liver-protecting and anti-uric acid emblica and hovenia dulcis pressed candy, which comprises an emblica emblica extract, a hovenia dulcis extract, a prebiotic, a disintegrant, a flavoring agent and a lubricant.

[0013] According to one embodiment of the present invention, the weight ratio of the emblica fruit extract to the Hovenia dulcis fruit extract is (1.2-1.8):1. Specifically, by weight, the emblica fruit extract is 20%-40%, the Hovenia dulcis fruit extract is 15%-35%, the prebiotic is 10%-25%, the disintegrant is 5%-15%, the flavoring agent is 8%-20%, and the lubricant is 0.5%-2%.

[0014] Ellagic acid from Phyllanthus emblica extract protects the liver and scavenges free radicals. Dihydromyricetin from Hovenia dulcis extract inhibits xanthine oxidase and reduces uric acid. Fructooligosaccharides are prebiotics, regulating intestinal flora and promoting uric acid excretion. Microcrystalline cellulose is a disintegrant to improve solubility, and xylitol is a flavoring to mask the bitterness. Magnesium stearate is a lubricant to prevent sticking.

[0015] The liver-protecting and anti-uric acid-fighting emblica and hovenia dulcis pressed candy of the present invention can increase the urate synthase inhibition rate by 40% (compared with a single prescription) when the ratio of emblica extract:hovenia dulcis extract is controlled at (1.2-1.8):1. The addition of oligofructose can enhance the expression of intestinal uric acid transporter, forming a dual-pathway mechanism of "inhibiting synthesis + promoting excretion" with the plant extract, thereby effectively enhancing the liver-protecting and anti-uric acid effects.

[0016] like Figure 1 As shown, the present invention also provides a preparation method of liver-protecting and anti-uric acid-resistant emblica and hovenia dulcis tablet candies, comprising: S1, crushing the emblica fruits through a 60-mesh sieve, using ethanol:water = 1:3 as a solvent, a solid-liquid ratio of 1:15 (g / mL), performing ultrasonic extraction at 60°C twice, each time for 30 minutes, and concentrating the combined extracts to a solid content of 25%.

[0017] Then in S2, the seeds of Hovenia dulcis were crushed and passed through an 80-mesh sieve, and pure water was used as the solvent with a solid-liquid ratio of 1:12 (g / mL), and heat extracted twice at 70°C for 1.5 hours each time, and the combined extracts were concentrated to a solid content of 25%. Then in S3, the concentrated solution obtained in S1 and the concentrated solution obtained in S2 are mixed in a volume ratio of 3:2, 20% of the weight of the mixed solution of maltodextrin is added, and the mixture is centrifugally spray-dried to obtain a composite powder.

[0018] S4. The composite powder was three-dimensionally mixed with oligofructose and microcrystalline cellulose for 30 minutes, xylitol was added and mixed for 15 minutes, and finally magnesium stearate was added and mixed for 5 minutes.

[0019] S5. Press into tablets under a pressure of 18±2KN.

[0020] Example 1: Emblica officinalis extract 30%, Hovenia dulcis extract 25%, Fructooligosaccharides 20%, Microcrystalline Cellulose 15%, Xylitol 9.5%, Magnesium Stearate 0.5%; Comparative Example 1 is the same as Example 1 except that the content of the emblica fruit extract is 35% and the Hovenia dulcis fruit extract is not included.

[0021] Comparative Example 2 contains 35% of Hovenia dulcis fruit extract and does not contain Emblica officinalis fruit extract, and the rest is the same as the example.

[0022] The experimental data comparison is as follows: Group Formula composition Active ingredient content (per tablet) Example 1 Emblica officinalis extract 30% + Hovenia dulcis extract 25% Ellagic acid 40mg + dihydromyricetin 35mg Comparative Example 1 Emblic Extract 55% (excluding Hovenia dulcis) Ellagic acid 74mg Comparative Example 2 Hovenia dulcis (Hovenia aurantium) extract 55% (excluding emblica) Dihydromyricetin 77mg Note: The total extract dosage of the single-formula group was equivalent to that of the compound-formula group (55%) to ensure dosage comparability.

[0023] Comparison of key experimental data 1. In vitro xanthine oxidase inhibition rate (core mechanism of uric acid lowering) Group Inhibition rate (%) Differences from the compound group Example Group 82.3±1.8 - Comparative Example 1 (Emblica officinalis) 38.5±2.1 ↓43.8% Comparative Example 2 (Hovenia dulcis) 62.7±1.9 ↓19.6% Theoretical superposition value* 65.9 ↓16.4% *Theoretical superposition value = Phyllanthus emblica inhibition rate × 55 / 40 + Hovenia dulcis inhibition rate × 55 / 35 (converted according to the dosage of active ingredients) Conclusion: The actual effect of the compound is significantly higher than the theoretical superposition value (p<0.01), demonstrating synergistic effect.

[0024] 2. Mouse Alcoholic Liver Injury Model (Hepatoprotective Effect) Detection indicators Example Group Comparative Example 1 Comparative Example 2 Serum ALT (U / L) 76.2±6.3 102.4±8.9 110.7±9.5 Liver tissue GSH (μmol / g) 9.8±0.7 7.2±0.5 6.9±0.6 Conclusion: The ALT-lowering effect of the compound group was 25.3% and 31.2% higher than that of the control group 1 / 2, respectively; the GSH (antioxidant marker) recovery ability of the compound group was significantly better than that of the single group (p<0.05).

[0025] 3. Hyperuricemia Model (Blood Uric Acid Level) Group Serum uric acid (μmol / L) Decrease vs Model Group Model Group 398.6±35.2 - Example Group 247.3±28.1 ↓37.9% Comparative Example 1 321.7±30.5 ↓19.3% Comparative Example 2 285.4±29.8 ↓28.4% Conclusion: The uric acid-lowering effect of the compound formula is 9.5% higher than that of control example 2 (using Hovenia dulcis alone).

[0026] This invention, by combining Phyllanthus emblica and Hovenia dulcis in a specific ratio (1.2-1.8:1), achieves synergistic liver-protecting and uric acid-lowering benefits in a compressed candy for the first time. Its xanthine oxidase inhibition rate (82.3%) significantly exceeds both the single formula and the theoretical summation value (p<0.01). The co-spray drying process combined with oligofructose excipients preserves the stability of the active ingredients (6-month retention rate >90%) while also improving the bitter taste of traditional Chinese medicine (with xylitol flavor correction). The compressed tablets disintegrate quickly (≤3 minutes) and are portable, addressing the long-term medication compliance challenges faced by patients with high uric acid levels, demonstrating significant clinical value and market competitiveness.

[0027] The above description is merely one embodiment of the present invention and is not intended to limit the present invention. Those skilled in the art will readily appreciate that the present invention is susceptible to various modifications and variations. Any modifications, equivalent substitutions, or improvements made within the spirit and principles of the present invention shall be included within the scope of protection of the present invention.

Claims

1. A liver-protecting and anti-uric acid candy containing emblica emblica and Hovenia dulcis fruit tablets, characterized in that: The invention comprises an extract of emblica fruit, an extract of Hovenia dulcis, a prebiotic, a disintegrant, a flavoring agent and a lubricant, wherein the weight ratio of the emblica fruit extract to the Hovenia dulcis fruit extract is (1.2-1.8):

1.

2. The liver-protecting and anti-uric acid-resistant emblica and Hovenia dulcis fruit tablet candy according to claim 1, characterized in that: In parts by weight, the extract of emblica buds is 20%-40%, the extract of Hovenia dulcis is 15%-35%, the prebiotic is 10%-25%, the disintegrant is 5%-15%, the flavoring agent is 8%-20%, and the lubricant is 0.5%-2%.

3. The liver-protecting and anti-uric acid-resistant emblica and Hovenia dulcis fruit tablet candy according to claim 2, characterized in that: The prebiotic is oligofructose, the disintegrant is microcrystalline cellulose, the flavoring agent is xylitol, and the lubricant is magnesium stearate.

4. A method for preparing the liver-protecting and anti-uric acid-resistant emblica and Hovenia dulcis tablet candy according to any one of claims 1 to 3, characterized in that: include: S1. Grind the emblica fruit through a 60-mesh sieve and extract twice with ultrasonic wave at 60°C for 30 min each time using ethanol:water = 1:3 as solvent and solid-liquid ratio of 1:15 (g / mL). The combined extracts were concentrated to a solid content of 25%. S2. Grind the seeds of Hovenia dulcis and pass them through an 80-mesh sieve. Use pure water as the solvent at a solid-liquid ratio of 1:12 (g / mL). Perform heat extraction at 70°C twice, each time for 1.5 hours. Concentrate the combined extracts to a solid content of 25%. S3, mixing the concentrated solution obtained in S1 and the concentrated solution obtained in S2 in a volume ratio of 3:2, adding 20% ​​maltodextrin by weight of the mixed solution, and centrifugally spray drying to obtain a composite powder; S4, three-dimensionally mixing the composite powder with oligofructose and microcrystalline cellulose for 30 minutes, adding xylitol and mixing for 15 minutes, and finally adding magnesium stearate and mixing for 5 minutes; S5. Press into tablets under a pressure of 18±2KN.

Images